Neutrophil count and the inflammation-based glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 2, 2014, Pages 945-950

  Li, Qing Qing ^a   Lu, Zhi Hao ^a   Yang, Li ^b   Lu, Ming ^a   Zhang, Xiao Tian ^a   Li, Jian ^a   Zhou, Jun ^a   Wang, Xi Cheng ^a   Gong, Ji Fang ^a   Gao, Jing ^a   Li, Jie ^a   Li, Yan ^a   Shen, Lin ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b Zhangzhou Municipal Hospital   (China)

Author keywords

Gastric cancer; Glasgow prognostic score (GPS); Overall survival; Systemic inflammation

Indexed keywords

ANTINEOPLASTIC AGENT; AUTACOID;

AGED; ARTICLE; CANCER STAGING; FEMALE; FOLLOW UP; HUMAN; IMMUNOLOGY; INFLAMMATION; LIVER TUMOR; LUNG TUMOR; LYMPHOCYTE; MALE; METABOLISM; METASTASIS; MORTALITY; NEUTROPHIL; PATHOLOGY; PERITONEUM TUMOR; PROGNOSIS; STOMACH TUMOR; SURVIVAL RATE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHOCYTES; MALE; NEOPLASM STAGING; NEUTROPHILS; PERITONEAL NEOPLASMS; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84894670021     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.2.945     Document Type: Article

References (45)

1. Aliustaoglu M, Bilici A, Ustaalioglu BB, et al (2010). The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment. Med Oncol, 27, 1060-5.
2. Al-Shaiba R, McMillan DC, Angerson WJ, et al (2004). The relationship between hypoalbuminaemia, tumour volume and the systemic inflammatory response in patients with colorectal liver metastases. Br J Cancer, 91, 205-7.
3. Asher V, Lee J, Innamaa A, et al (2011). Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol, 13, 499-503.
4. Cho H, Hur HW, Kim SW, et al (2009). Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother, 58, 15-23.
5. Chua W, Charles KA, Baracos VE, et al (2011). Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer, 104, 1288-95.
6. Colotta F, Allavena P, Sica A, et al (2009). Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis, 30, 1073-81.
7. Crumley AB, McMillan DC, McKernan M, et al (2006). Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer, 94, 637-41.
8. Crumley AB, Stuart RC, McKernan M, et al (2010). Is hypoalbuminemia an independent prognostic factor in patients with gastric cancer? World J Surg, 34, 2393-8.
9. Dalpiaz O, Ehrlich GC, Mannweiler S, et al (2013). Validation of the pre-treatment neutrophil-lymphocyte ratio as prognostic factor in a European cohort of patients with upper tract urothelial carcinoma. Bju Int??.
10. Fondevila C, Metges JP, Fuster J, et al (2004). p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer, 90, 206-15.
11. Fox P, Hudson M, Brown C, et al (2013). Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. Br J Cancer, 109, 147-53.
12. Glimelius B, Ekstrom K, Hoffman K, et al (1997). Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol, 8, 163-8.
13. Hanahan D, Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell, 144, 646-74.
14. He W, Yin C, Guo G, et al (2013). Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer. Med Oncol, 30, 439.
15. Herszenyi L, Tulassay Z (2010). Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci, 14, 249-58.
16. Hwang JE, Kim HN, Kim DE, et al (2011). Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer. Bmc Cancer, 11, 489.
17. Jeong JH, Lim SM, Yun JY, et al (2012). Comparison of two inflammation-based prognostic scores in patients with unresectable advanced gastric cancer. Oncology, 83, 292-9.
18. Jiang X, Hiki N, Nunobe S, et al (2012). Prognostic importance of the inflammation-based Glasgow prognostic score in patients with gastric cancer. Br J Cancer, 107, 275-9.
19. Jung MR, Park YK, Jeong O, et al (2011). Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol, 104, 504-10.
20. Kanda M, Fujii T, Kodera Y, et al (2011). Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg, 98, 268-74.
21. Kao SC, Pavlakis N, Harvie R, et al (2010). High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res, 16, 5805-13.
22. Kasymjanova G, MacDonald N, Agulnik JS, et al (2010). The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer. Curr Oncol, 17, 52-8.
23. Kishi Y, Kopetz S, Chun YS, et al (2009). Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol, 16, 614-22.
24. Kusumanto YH, Dam WA, Hospers GA, et al (2003). Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis, 6, 283-7.
25. Kwon HC, Kim SH, Oh SY, et al (2012). Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers, 17, 216-22.
26. Lee S, Oh SY, Kim SH, et al (2013). Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. Bmc Cancer, 13, 350.
27. Leitch EF, Chakrabarti M, Crozier JE, et al (2007). Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer, 97, 1266-70.
28. Lord BI, Bronchud MH, Owens S, et al (1989). The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci U S A, 86, 9499-503.
29. Maconi G, Manes G, Porro GB (2008). Role of symptoms in diagnosis and outcome of gastric cancer. World J Gastroenterol, 14, 1149-55.
30. Mahmoud FA, Rivera NI (2002). The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep, 4, 250-5.
31. Mantovani A, Allavena P, Sica A, et al (2008). Cancer-related inflammation. Nature, 454, 436-44.
32. McMillan DC (2013). The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev, 39, 534-40.
33. Murad AM, Santiago FF, Petroianu A, et al (1993). Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer, 72, 37-41.
34. Nozoe T, Ninomiya M, Maeda T, et al (2010). Prognostic nutritional index: a tool to predict the biological aggressiveness of gastric carcinoma. Surg Today, 40, 440-3.
35. Oba K, Paoletti X, Bang YJ, et al (2013). Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. Eur J Cancer, 49, 1565-77.
36. Onate-Ocana LF, Aiello-Crocifoglio V, Gallardo-Rincon D, et al (2007). Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol, 14, 381-9.
37. Proctor MJ, Morrison DS, Talwar D, et al (2011). A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer, 47, 2633-41.
38. Pyrhonen S, Kuitunen T, Nyandoto P, et al (1995). Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer, 71, 587-91.
39. Rothwell PM, Fowkes FG, Belch JF, et al (2011). Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet, 377, 31-41.
40. Sarraf KM, Belcher E, Raevsky E, et al (2009). Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg, 137, 425-8.
41. Sugiura T, Uesaka K, Kanemoto H, et al (2013). Elevated Preoperative Neutrophil-to-lymphocyte Ratio as a Predictor of Survival After Gastroenterostomy in Patients with Advanced Pancreatic Adenocarcinoma. Ann Surg Oncol, 20, 4330-7.
42. Szkandera J, Gerger A, Liegl-Atzwanger B, et al (2013). Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients. Br J Cancer, 109, 2316-22.
43. Ulich TR, Del CJ, Keys M, et al (1987). Kinetics and mechanisms of recombinant human interleukin 1 and tumor necrosis factor-alpha-induced changes in circulating numbers of neutrophils and lymphocytes. J Immunol, 139, 3406-15.
44. Xia WX, Ye YF, Lu X, et al (2013). The Impact of Baseline Serum C-Reactive Protein and C-Reactive Protein Kinetics on the Prognosis of Metastatic Nasopharyngeal Carcinoma Patients Treated with Palliative Chemotherapy. PLoS One, 8, e76958.
45. Yamanaka T, Matsumoto S, Teramukai S, et al (2007). The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology, 73, 215-20.